September 17, 2021

Announce the formation of a business alliance with Fresenius Medical Care

We have formed a business alliance in the field of home dialysis in Japan with Fresenius MedicalCare, the world's leading provider of products and services for people with chronic kidney failure.
JMS Co., Ltd. (address: Hiroshima, Japan, Representative Director: Hiroaki Okukubo) and Fresenius
Medical Care Japan K.K. have reached a basic agreement on a business alliance in the field of homedialysis in Japan. Under the government promotion policy of home medical care, both parties will work
together to expand our home dialysis business by providing services that meet the changing lifestyles anddiversifying needs of patients with chronic kidney failure.
Dialysis therapy for chronic kidney failure patients mainly includes hemodialysis in hospital and hometherapies. We are the only one company in Japan to manufacture and sell both of these products. Fresenius
Medical Care is a leading company in the global dialysis market and has a rich product portfolio, in hometherapies which has become increasingly popular in recent years, from peritoneal dialysis related products
to home hemodialysis, as it provides high quality products to help patients choose the appropriate dialysis
therapy according to their lifestyle. We have decided that it is not only high affinity with our dialysis
business, but also the most suitable partner to create new innovation.

Hemodialysis

Aiming to popularize home dialysis
Peritoneal dialysis
Home hemodialysis＜Types of Dialysis Therapy＞

Patients with chronic kidney
failure receive dialysis
therapy to get uremia out ofthe bodyDialysis site
Main frequency

Hospital
2-3 times a week

APD treatments aresupported by a machineHome or Work
4-6 times a dayHome
4-6 times a week

Background of Business Alliance The number of dialysis patients for chronic kidney failure in Japan is increasing by about 5,000 every year.
 In Japan, more than 90% of hemodialysis treatment is performed in hospitals.
 The number of patients who prefer home therapy with a high degree of freedom is increasing due to changes
in lifestyle and diversification of needs.
Purpose and Content of the Business Alliance By forming a business alliance with Fresenius Medical Care, we will increase the penetration rate of homedialysis therapy in Japan and contribute to improving the QOL of dialysis patients.
 First, Fresenius Medical Care's home dialysis-related products will be added to the Company's product lineup
to strengthen the product portfolio, and business collaboration will be promoted through cooperation inlogistics operations, etc.
 Furthermore, the two companies plan to start discussions on initiatives such as the development andintroduction of new technologies and products that meet the individual needs of dialysis patients.
Inquiries: JMS Co., Ltd. Corporate Planning Department

1/2E-mail: pub-bpd@jms.cc

Fresenius Medical Care Japan Co., Ltd. Profile(1) Name

Fresenius Medical Care Japan K.K.

(2) Location

2-7 Kaimo, Buzen, Fukuoka, 828-0045, Japan(3) Date Established

October, 1993

(4) Representative

Jean Desombre(5) Capital

80 million yen(Fresenius Medical Care AG & Co.KGaA 100% ownership)(6) Business

Import, manufacture and sale of artificial dialysis machinesand dialyzer for dialysis Import, export, manufacture andsale of peritoneal dialysate and related medical devices

About Fresenius Medical Care

Fresenius Medical Care is the world's leading provider ofproducts and services for people with chronic kidney
failure of which around 3.7 million patients worldwide
regularly undergo dialysis treatment. Through its networkof 4,092 dialysis clinics, Fresenius Medical Care provides
dialysis treatments for 346,553 patients around the globe.
Fresenius Medical Care is also the leading provider of
dialysis products such as dialysis machines or dialyzers.
Along with its core business, the Renal Care Continuum,
the company focuses on expanding in complementary areasand in the field of critical care. Fresenius Medical Care islisted on the Frankfurt Stock Exchange (FME) and on theNew York Stock Exchange (FMS).
For more information visit the Company’s website athttps//www.freseniusmedicalcare.com
https//www.freseniusmedicalcare.asia

The forward-looking statements contained in this release are based on currently available information and include
a variety of potential risks and uncertainties, including major changes in social conditions. Please note that thisinformation is as of the date of issue and is subject to change in the future.

2/2